The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Topic

Videos

In August 2026, Heidi Overton was nominated for FDA commission, and a wave of oncology and neuro drugs were approved.

Regulatory Roundup—August 2026

Chris Williams serves as executive director, Analytical Development ILM at Alcami, bringing more than a decade of experience in analytical development, quality control, and laboratory operations.

He earned a Bachelor of Science in Chemistry in 2010 and a Master of Science in Chemistry in 2011 from East Carolina University. Chris joined AAI, now Alcami, in 2011 as a Development/QC Scientist. In 2013, he began supervising a laboratory team focused on high-throughput manufacturing release. In 2014, he moved into the management of development services and has since progressed to oversee elemental impurities, biologics, extractables and leachables, nitrosamines, specialty testing, raw material release, microbiology, and all Wilmington laboratory operations.

Articles

Nitrosamine control is about understanding why nitrosamines form, where they may form, and how to prevent their formation.

From Detection to Prediction: Analytical Approaches for Nitrosamine Risk

Lilly is set to acquire Merida Biosciences for up to $2.875B, gaining a precision autoantibody-degrading platform led by phase 1 candidate MER511.

Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases

This week’s PharmTech.com content covered AI agent authority, hold-time and nitrosamine risk frameworks, biologics formulation, 3D bioprinting, and major oncology and dealmaking news.

PharmTech Weekly Roundup—August 28, 2026

Robert Dream is managing director of HDR Company and a member of PharmTech’s Editorial Advisory Board. 

In part 2 of his overview on hold times in biopharmaceuticals, Robert Dream details the regulations that govern hold times and how to mitigate risks that can occur during hold times.

Pharma Fundamentals: Risks and Regulations for Hold Times in Biopharmaceuticals

Cheryl Barton is director of PharmaVision, 

European biotechs are advancing bioinks and high-resolution bioprinting for medical devices and regenerative tissues.

3D Printing Revolutionizing Tissue Engineering and Regenerative Medicine in Europe 

McKesson will acquire Precision Medicine Group for $2.25B, integrating clinical research and commercialization services within its oncology segment.

What the McKesson-Precision Medicine Deal Signals for Trial Sponsors

The FDA grants accelerated approval to Ultragenyx's Genglycos, the first gene therapy for GSDIa, raising manufacturing and post-market monitoring questions.

GSDIa Gene Therapy Approval Signals New Path for Rare Disease Manufacturing

Postmarketing governance must be evidenced across the full life cycle—design, validation, and live monitoring—not documented once and assumed to hold.

How AI Can Assist With Postmarketing Changes

VP Operational Delivery, PPD FSP Solutions, part of the PPD clinical research business of Thermo Fisher Scientific

Samantha Hadfield, PPD, explains how mixed FSP/FSO models help sponsors balance speed, cost, and complexity in clinical trial outsourcing.